Why Revolution Medicines Shares Are Trading Higher Today
Revolution Medicines, Inc. (NASDAQ: RMVD) shares are trading higher after the company reported better-than-expected fourth-quarter results.
Revolution Medicines’ Early-Data Validation For Cancer Program Wins Price Target Boost By This Analyst
Needham increased the price target for Revolution Medicines Inc (NASDAQ:RVMD) from $32 to $38 with a Buy rating. In its Q4 earnings release, Revolution…
Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $35
Oppenheimer analyst Jay Olson maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $30 to $35.
Needham Maintains Buy on Revolution Medicines, Raises Price Target to $38
Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $32 to $38.
JP Morgan Upgrades Revolution Medicines to Overweight, Raises Price Target to $38
JP Morgan analyst Eric Joseph upgrades Revolution Medicines (NASDAQ:RVMD) from Neutral to Overweight and raises the price target from $32 to $38.
Revolution Medicines Q4 EPS $(0.63) Beats $(0.82) Estimate, Sales $15.33M Beat $7.75M Estimate
Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.82) by 23.17 percent. This is a 11.27 percent increase over losses of $(0.71) per share
Needham Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $31
Needham analyst Ami Fadia initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Buy rating and announces Price Target of $31.
Chefs’ Warehouse, Chart Industries And Some Other Big Stocks Moving Lower On Thursday
U.S. stocks traded higher, with the Dow Jones jumping over 200 points on Thursday. Here are some big stocks recording losses in today’s session.
Revolution Medicines Regains Global Rights To Mid-Stage Cancer Program As Sanofi Terminates Collaboration
Revolution Medicines Inc (NASDAQ:RVMD) announced that Sanofi SA (NASDAQ:SNY) has terminated global SHP2 development and commercialization collaboration. Following termination, Revolution Medicines will…
HC Wainwright & Co. Maintains Buy on Revolution Medicines, Lowers Price Target to $30
HC Wainwright & Co. analyst Robert Burns maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and lowers the price target from $37 to $30.